The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
SELLAS Life Sciences Group, Inc. has announced significant milestones in its clinical development of cancer therapies. An Independent Data Monitoring Committee will conduct an interim analysis of the ...
Advancements in Interoperability: Achieving Anatomic Pathology Reports That Adhere to International Standards and Are Both Human-Readable and Readily Computable Favorable, intermediate, and adverse ...
Foghorn Therapeutics Inc. FHTX recently announced that the FDA has placed a full clinical hold on the phase I dose escalation study of pipeline candidate FHD-286 in relapsed and/or refractory acute ...
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are cancers of the blood and bone marrow. The main difference between the two is the type of white blood cell they impact. In AML, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results